<DOC>
	<DOCNO>NCT00000689</DOCNO>
	<brief_summary>To determine toxicity effectiveness add sargramostim ( recombinant granulocyte-macrophage colony stimulate factor ; GM-CSF ) standard chemotherapy drug combination ( methotrexate , bleomycin , doxorubicin , cyclophosphamide , vincristine , dexamethasone ) know mBACOD treatment non-Hodgkin 's lymphoma patient infected HIV . Treatment patient AIDS-associated lymphoma achieve inferior result compare outcomes non-AIDS patient . Treatment mBACOD promising , toxicity high . Patients treat mBACOD low white blood cell count . GM-CSF increase number white blood cell animal study preliminary human study . It hop include GM-CSF among drug give lymphoma patient prevent lessen decrease white blood cell cause mBACOD .</brief_summary>
	<brief_title>Phase I Trial mBACOD Granulocyte-Macrophage Colony-Stimulating Factor ( GM-CSF ) AIDS-Associated Large Cell , Immunoblastic , Small Non-cleaved Lymphoma</brief_title>
	<detailed_description>Treatment patient AIDS-associated lymphoma achieve inferior result compare outcomes non-AIDS patient . Treatment mBACOD promising , toxicity high . Patients treat mBACOD low white blood cell count . GM-CSF increase number white blood cell animal study preliminary human study . It hop include GM-CSF among drug give lymphoma patient prevent lessen decrease white blood cell cause mBACOD . Patients admit study receive chemotherapy 21-day cycle . The length therapy , 2 - 8 month , depend tumor responds treatment . Four medicine give day 1 cycle vein ( IV ) ( doxorubicin , cyclophosphamide , bleomycin , vincristine ) . Dosages doxorubicin cyclophosphamide increase later group patient toxicity first group tolerable . A fifth medicine ( dexamethasone ) give mouth ( PO ) day 1 - 5 cycle sixth medicine ( methotrexate ) give IV day 15 cycle . Leucovorin give methotrexate prevent methotrexate side effect . GM-CSF treatment start day 3 continue 11 day . To prevent spread tumor , spinal tap do 4 occasion inject cytosine arabinoside directly spinal fluid . If tumor cell present spinal fluid , patient also take cytosine arabinoside spinal tap 3 x/week tumor cell disappear monthly interval 1 year . Patients tumor cell spinal fluid also give radiation treatment head .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Inclusion Criteria Patients must : Positive HIV antibody ELISA Western blot confirmation , positive HIV culture serum p24 antigen capture assay , prior diagnosis AIDS CDC surveillance criterion . Pathological diagnosis large cell ( cleave noncleaved ) , immunoblastic , small noncleaved lymphoma , stage I , II , III , IV . If displaying systemic ( `` B '' ) symptom , evaluation concurrent opportunistic infection follow : Buffy coat Mycobacterium intracellulareavium ( MAI ) cytomegalovirus ( CMV ) culture ; serum cryptococcal antigen ; measure pulmonary function exclude Pneumocystis carinii pneumonia include chest xray either gallium scan , blood gas , DLCO ; stool culture special stain Salmonella , Isospora belli , cryptosporidium , CMV , MAI patient diarrhea ; computerize tomography ( CT ) scan magnetic resonance imaging ( MRI ) brain , lumbar puncture India ink , acidfast bacillus smear , cryptococcal antigen , fungal/mycobacterial culture . Bone marrow involvement permit patient meet hematologic criterion . Patients central nervous system ( CNS ) involvement diagnosis diagnose treatment receive cranial radiotherapy : The total dose 2400 rad deliver rate 200 rads/day mid plane employ parallel opposing , lateral whole brain field . The low border field encompass C2 cover meninges . Patients treat 5 days/week , Monday Friday , total prescribe dose complete . Radiation begin soon possible documentation lymphomatous disease CNS . If second course treatment require , 2400 rad well within whole brain tolerance normal tissue ( 45005000 rad ) . Exclusion Criteria Coexisting Condition : Patients follow exclude : Acute bacterial opportunistic infection . Second primary cancer Kaposi 's sarcoma , nonmelanoma skin cancer , carcinoma insitu cervix . Primary central nervous system ( CNS ) lymphoma . Concurrent Medication : Excluded : Patients receive prophylactic maintenance therapy bacterial opportunistic infection , exception receive Fansidar ( sulfadoxine / pyrimethamine ) Pneumocystis carinii pneumonia prophylaxis . Antiretroviral agent . Immunomodulators . Patients follow exclude : Acute bacterial opportunistic infection . Second primary cancer Kaposi 's sarcoma , nonmelanoma skin cancer , carcinoma insitu cervix . Primary central nervous system ( CNS ) lymphoma . Prior Medication : Excluded : Prior therapy lymphoma . Excluded within 1 week study entry : Antiretroviral agent immunomodulators . Prior Treatment : Excluded : Prior therapy lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>M-BACOD protocol</keyword>
	<keyword>Nervous System Neoplasms</keyword>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Injections , Intravenous</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antineoplastic Agents , Combined</keyword>
</DOC>